REVVITY, INC. (RVTY): Results of Operations and Financial Condition
REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pressrelease.htm EX-99.1 Document FOR IMMEDIATE RELEASE August 4, 2026 Revvity Announces Financial Results for the Second Quarter of 2026 • Revenue of $730 million; pro forma revenue of $711 million; 4% pro forma revenue growth; 3% pro forma organic revenue growth
How this was made
The 30-second read
Why it matters
The combination of a Q2 beat versus expectations (management commentary), a raised full-year pro forma EPS and revenue outlook, and a definitive China divestiture agreement creates two tradable drivers: near-term earnings/guidance positioning and longer-dated execution/regulatory risk.
Market read
This is a primary earnings-and-guidance update plus a definitive strategic divestiture disclosure, both of which can reprice the stock and change forward estimates.
What to watch
Traders should monitor how the company defines and reconciles pro forma versus GAAP going forward, and whether regulatory approvals for the China IDX divestiture introduce delays or conditions that affect 2027 earnings power.
Background
Revvity filed an SEC 8-K (Item 2.02) with a Q2 2026 results press release and provided full-year 2026 pro forma guidance. The release also states it entered a definitive agreement to divest its China Immunodiagnostics business (China IDX).
Ticker impact
Revvity reported Q2 results and raised full-year 2026 pro forma guidance, while also announcing a definitive agreement to divest its China Immunodiagnostics business.
Likely positive bias on guidance raise, with additional volatility around details/assumptions of the China IDX divestiture and its impact on reported versus pro forma metrics.
The filing discloses both a guidance change (actionable for positioning) and a definitive divestiture agreement (material strategic overhang), but it provides limited detail on proceeds, timing mechanics beyond expected close by end-2027, and how guidance is adjusted for the divestiture.
Market effects
Diagnostics and life-sciences tools peers may see read-across on demand momentum and margin resilience, but the China divestiture is company-specific.
China exposure is reduced for Revvity over time, potentially shifting competitive dynamics in China immunodiagnostics.
Tariff-related refunds are cited as a contributor to pro forma results, which could influence sentiment around cross-border supply chains for the sector.
Counterpoint
Raised pro forma guidance may be partly supported by tariff-related refunds and pro forma adjustments that exclude China IDX, so underlying demand durability could be less strong than headline numbers imply.
Key entities
- companyRevvity, Inc.
NYSE-listed life sciences and diagnostics company reporting Q2 2026 results, raising full-year 2026 pro forma guidance, and agreeing to divest China Immunodiagnostics (China IDX).
- business_unitChina Immunodiagnostics business (China IDX)
Immunodiagnostics business in China representing about 6% of fiscal 2025 revenue, expected to close by end-2027 subject to approvals.
